H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Can-Fite BioPharma (NYSE: CANF) today and set a price target of $8. The company’s shares closed yesterday at $1.23, close to its 52-week low of $1.18.
According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.1% and a 37.6% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Cytori Therap, and Mesoblast Ltd.
Can-Fite BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $8.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.75 and a one-year low of $1.18. Currently, Can-Fite BioPharma has an average volume of 188.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602.
